AOP:7 | Aromatase (Cyp19a1) reduction leading to impaired fertility in adult female | Reproductive System Disease; Endocrine System Disease; Reproductive System Disease | Under Review | 0.2 | KE:408 | reduction in ovarian granulosa cells, Aromatase (Cyp19a1) |
AOP:8 | Upregulation of Thyroid Hormone Catabolism via Activation of Hepatic Nuclear Receptors, and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Nervous System Disease | Under Development | 0.11 | KE:239 | Activation, Pregnane-X receptor, NR1l2 |
AOP:19 | Androgen receptor antagonism leading to adverse effects in the male foetus (mammals) | Reproductive System Disease | - | 0.2 | KE:26 | Antagonism, Androgen receptor |
AOP:25 | Aromatase inhibition leading to reproductive dysfunction | Unclassified | WPHA/WNT Endorsed | 0.12 | KE:36 | Inhibition, Aromatase |
AOP:30 | Estrogen receptor antagonism leading to reproductive dysfunction | Unclassified | Under Review | 0.17 | KE:112 | Antagonism, Estrogen receptor |
AOP:60 | NR1I2 (Pregnane X Receptor, PXR) activation leading to hepatic steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.08 | KE:245 | Activation, PXR/SXR |
AOP:111 | Decrease in androgen receptor activity leading to Leydig cell tumors (in rat) | Cancer; Reproductive System Disease | - | 0.2 | KE:1614 | Decrease, androgen receptor activation |
AOP:123 | Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcription | Unclassified | - | 0.27 | KE:799 | Increased, HIF-1 heterodimer |
KE:801 | modulation, Unknown |
KE:802 | Increased, HIF-1 alpha transcription |
AOP:290 | Mitochondrial ATP synthase antagonism leading to growth inhibition (1) | Unclassified | - | 0.25 | KE:1785 | Increase, Mitochondrial ATP synthase antagonism |
AOP:291 | Mitochondrial ATP synthase antagonism leading to growth inhibition (2) | Unclassified | - | 0.25 | KE:1785 | Increase, Mitochondrial ATP synthase antagonism |
AOP:300 | Thyroid Receptor Antagonism and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | Under Development | 0.2 | KE:1656 | Antagonism, Thyroid Receptor |
AOP:306 | Androgen receptor (AR) antagonism leading to short anogenital distance (AGD) in male (mammalian) offspring | Unclassified | Under Development | 0.5 | KE:1614 | Decrease, androgen receptor activation |
KE:26 | Antagonism, Androgen receptor |
AOP:344 | Androgen receptor (AR) antagonism leading to nipple retention (NR) in male (mammalian) offspring | Unclassified | Under Development | 0.5 | KE:1614 | Decrease, androgen receptor activation |
KE:26 | Antagonism, Androgen receptor |
AOP:345 | Androgen receptor (AR) antagonism leading to decreased fertility in females | Endocrine System Disease; Reproductive System Disease; Reproductive System Disease | Under Development | 0.33 | KE:1614 | Decrease, androgen receptor activation |
KE:26 | Antagonism, Androgen receptor |
AOP:346 | Aromatase inhibition leads to male-biased sex ratio via impacts on gonad differentiation | Unclassified | WPHA/WNT Endorsed | 0.2 | KE:36 | Inhibition, Aromatase |
AOP:372 | Androgen receptor antagonism leading to testicular cancer | Endocrine System Disease; Reproductive System Disease; Cancer | - | 0.4 | KE:1614 | Decrease, androgen receptor activation |
KE:26 | Antagonism, Androgen receptor |
AOP:440 | Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia | Benign Neoplasm; Endocrine System Disease; Reproductive System Disease; Reproductive System Disease; Cancer; Endocrine System Disease | Under Development | 0.11 | KE:1046 | Suppression, Estrogen receptor (ER) activity |
AOP:445 | Estrogen Receptor Alpha Agonism leads to Impaired Reproduction | Reproductive System Disease | - | 0.12 | KE:1065 | Activation, estrogen receptor alpha |
AOP:477 | Androgen receptor (AR) antagonism leading to hypospadias in male (mammalian) offspring | Physical Disorder | - | 0.67 | KE:1614 | Decrease, androgen receptor activation |
KE:26 | Antagonism, Androgen receptor |
AOP:485 | Thyroid hormone antagonism leading to impaired oligodendrocyte maturation during development and subsequent decreased cognition | Cognitive Disorder | - | 0.14 | KE:1656 | Antagonism, Thyroid Receptor |
AOP:503 | Activation of uterine estrogen receptor-alfa leading to endometrial adenocarcinoma, via epigenetic modulation | Reproductive System Disease; Cancer | Under Review | 0.17 | KE:1065 | Activation, estrogen receptor alpha |
AOP:517 | Pregnane X Receptor (PXR) activation leads to liver steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.2 | KE:239 | Activation, Pregnane-X receptor, NR1l2 |
AOP:525 | Reduced oligodendrocyte differentiation during neurodevelopment leading to impaired learning and memory | Developmental Disorder Of Mental Health | - | 0.15 | KE:1656 | Antagonism, Thyroid Receptor |
KE:2216 | Binding of antagonist to thyroid hormone receptor |
AOP:545 | Activation, Pregnane-X receptor, NR1l2 leads to increased plasma low-density lipoprotein (LDL) cholesterol via increased cholesterol synthesis | Unclassified | - | 0.2 | KE:239 | Activation, Pregnane-X receptor, NR1l2 |
AOP:548 | Activation, Pregnane-X receptor, NR1l2 leads to increased plasma low-density lipoprotein (LDL) cholesterol via increased PCSK9 protein expression | Unclassified | - | 0.2 | KE:239 | Activation, Pregnane-X receptor, NR1l2 |
AOP:549 | Aromatase inhibition leads to reproductive toxicity (including growth and developmental toxicity) in adult female zebrafish | Unclassified | - | 0.12 | KE:36 | Inhibition, Aromatase |